Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates

Journal of Clinical Microbiology
M A PfallerD J Diekema

Abstract

The influence of test variables on in vitro susceptibility testing of caspofungin was examined with 694 isolates of Candida albicans including seven laboratory-derived glucan synthesis mutants. The conditions providing the greatest separation between the mutant strains and the clinical isolates were RPMI medium, MIC end point criterion of partial inhibition, and incubation for 24 h. These testing conditions were then applied to 3,322 isolates of Candida spp. (3,314 clinical isolates and eight glucan synthesis mutants). Among the 11 isolates for which caspofungin MICs were >/=2 microg/ml, eight were accounted for by the glucan synthesis mutants. The MICs for >99% of isolates were </=1 microg/ml, and thus these isolates were differentiated from strains with reduced in vitro and in vivo susceptibilities to caspofungin.

References

Jul 1, 1997·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·P W NelsonJ H Rex
Nov 26, 1997·Antimicrobial Agents and Chemotherapy·K BartizalJ Balkovec
Jun 13, 1998·Antimicrobial Agents and Chemotherapy·M E KlepserM A Pfaller
Jul 14, 2001·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·A Hoang
Oct 2, 2002·Journal of Clinical Microbiology·M A Pfaller, D J Diekema
Dec 20, 2002·The New England Journal of Medicine·Jorge Mora-DuarteUNKNOWN Caspofungin Invasive Candidiasis Study Group
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Valérie Letscher-Bru, Raoul Herbrecht
Mar 26, 2003·Antimicrobial Agents and Chemotherapy·David Andes
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley C Deresinski, David A Stevens
Dec 10, 2003·Journal of Clinical Microbiology·Michael A PfallerDaniel J Diekema

❮ Previous
Next ❯

Citations

Sep 22, 2007·Medical Mycology·Sevtap Arikan
Apr 26, 2008·The Journal of Antimicrobial Chemotherapy·Theresa S RichardsTheodore C White
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Vânia Lúcia Ribeiro da MattaAnna S Levin
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Junichi MitsuyamaHirokazu Narita
May 16, 2007·Antimicrobial Agents and Chemotherapy·Palani PerumalW LaJean Chaffin
Oct 21, 2009·Antimicrobial Agents and Chemotherapy·V NagappanJ A Vazquez
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·M A PfallerB P Goldstein
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·Karl V ClemonsDavid A Stevens
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
Jun 16, 2005·Journal of Clinical Microbiology·M MitchellA Wright
Feb 4, 2006·Journal of Clinical Microbiology·S A MesserM A Pfaller
Mar 7, 2006·Journal of Clinical Microbiology·M A PfallerD J Diekema
May 3, 2007·Internal Medicine·Ryosuke TsurutaTsuyoshi Maekawa
Sep 16, 2015·Critical Reviews in Microbiology·Jessica C Song, David A Stevens
Apr 7, 2006·Expert Review of Anti-infective Therapy·Vicki A Morrison
Apr 26, 2006·Expert Opinion on Emerging Drugs·Michelle S TurnerJohn R Perfect
Jun 13, 2009·Current Medical Research and Opinion·Russell E Lewis
Apr 21, 2009·Clinics in Chest Medicine·Nancy L Wengenack, Matthew J Binnicker
Jun 17, 2008·Diagnostic Microbiology and Infectious Disease·Eveline van AsbeckDavid A Stevens
Oct 27, 2007·International Journal of Antimicrobial Agents·Pei-Lan ShaoPo-Ren Hsueh
Sep 21, 2006·Infectious Disease Clinics of North America·Peter G Pappas
Dec 17, 2008·Mycoses·Andreas GlöcknerOliver A Cornely
Feb 24, 2007·Pharmacotherapy·Diane Cappelletty, Kasi Eiselstein-McKitrick
Dec 2, 2005·Clinical Techniques in Small Animal Practice·Richard F Hector
Aug 28, 2004·Expert Opinion on Investigational Drugs·Michael A Pfaller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.